Bausch Health Announces 2025 Salix Gastrointestinal Health Scholars Program
Bausch Health (NYSE/TSX: BHC) and its GI business, Salix Pharmaceuticals, have announced their 2025 Salix Gastrointestinal Health Scholars Program. The initiative will provide ten scholarships of up to $10,000 each to students living with GI diseases who are pursuing higher education.
This marks the sixth consecutive year of the program, which supports students attending two- or four-year colleges, universities, or advanced vocational/technical schools for the 2025-2026 academic year. The scholarships are available in three categories: Undergraduate Scholar Awards, Graduate Scholar Awards, and Working and/or Single Parents Scholar Awards.
Applicants must complete an online application, submit reference letters, and write an essay about their GI condition's impact on their life and their healthcare provider's role. The application period closes on May 5, 2025, with winners to be announced in summer 2025.
Bausch Health (NYSE/TSX: BHC) e la sua divisione GI, Salix Pharmaceuticals, hanno annunciato il loro Programma di Borse di Studio per la Salute Gastrointestinale Salix 2025. L'iniziativa fornirà dieci borse di studio fino a $10.000 ciascuna a studenti affetti da malattie gastrointestinali che stanno perseguendo un'istruzione superiore.
Questo segna il sesto anno consecutivo del programma, che supporta gli studenti che frequentano college di due o quattro anni, università o scuole professionali/tecniche avanzate per l'anno accademico 2025-2026. Le borse di studio sono disponibili in tre categorie: Premi per Studenti Triennali, Premi per Studenti Laureati e Premi per Studenti Lavoratori e/o Genitori Single.
Gli aspiranti devono completare un'applicazione online, inviare lettere di referenze e scrivere un saggio sull'impatto della loro condizione GI sulla loro vita e sul ruolo del loro fornitore di assistenza sanitaria. Il periodo di candidatura si chiude il 5 maggio 2025, con i vincitori che saranno annunciati nell'estate del 2025.
Bausch Health (NYSE/TSX: BHC) y su negocio de GI, Salix Pharmaceuticals, han anunciado su Programa de Becas para la Salud Gastrointestinal 2025 de Salix. La iniciativa otorgará diez becas de hasta $10,000 cada una a estudiantes que padecen enfermedades gastrointestinales y que están cursando estudios superiores.
Este es el sexto año consecutivo del programa, que apoya a estudiantes que asisten a colegios de dos o cuatro años, universidades o escuelas técnicas/profesionales avanzadas para el año académico 2025-2026. Las becas están disponibles en tres categorías: Premios para Estudiantes de Pregrado, Premios para Estudiantes de Posgrado y Premios para Estudiantes Trabajadores y/o Padres Solteros.
Los solicitantes deben completar una solicitud en línea, enviar cartas de referencia y escribir un ensayo sobre el impacto de su condición GI en su vida y el papel de su proveedor de atención médica. El periodo de presentación de solicitudes finaliza el 5 de mayo de 2025, y los ganadores se anunciarán en el verano de 2025.
바우쉬 헬스 (NYSE/TSX: BHC)와 그 GI 사업부인 살릭스 제약이 2025년 살릭스 위장 건강 장학 프로그램을 발표했습니다. 이 initiative는 GI 질환을 앓고 있는 학생들에게 각 $10,000까지의 10개 장학금을 제공합니다.
이 프로그램은 2025-2026 학년도에 2년제 또는 4년제 대학, 대학교 또는 고급 직업/기술 학교에 재학 중인 학생들을 지원하는 여섯 번째 해를 맞이합니다. 장학금은 세 가지 카테고리로 제공됩니다: 학부 장학금, 대학원 장학금, 그리고 일하는 부모 및/또는 싱글 부모 장학금.
지원자는 온라인 신청서를 작성하고, 추천서를 제출하며, 자신의 GI 상태가 삶에 미친 영향과 의료 제공자의 역할에 대해 에세이를 작성해야 합니다. 신청 기간은 2025년 5월 5일에 종료되며, 수상자는 2025년 여름에 발표됩니다.
Bausch Health (NYSE/TSX: BHC) et son activité GI, Salix Pharmaceuticals, ont annoncé leur programme de bourses d'études pour la santé gastro-intestinale de Salix 2025. L'initiative accordera dix bourses allant jusqu'à 10 000 $ chacune à des étudiants vivant avec des maladies GI qui poursuivent des études supérieures.
C'est la sixième année consécutive du programme, qui soutient les étudiants fréquentant des collèges de deux ou quatre ans, des universités ou des écoles professionnelles/techniques avancées pour l'année universitaire 2025-2026. Les bourses sont disponibles dans trois catégories : Bourses d'Études pour Étudiants de Premier Cycle, Bourses d'Études pour Étudiants de Deuxième Cycle et Bourses d'Études pour Travailleurs et/ou Parents Célibataires.
Les candidats doivent remplir une demande en ligne, soumettre des lettres de référence et rédiger un essai sur l'impact de leur condition GI sur leur vie et le rôle de leur fournisseur de soins de santé. La période de candidature se termine le 5 mai 2025, et les gagnants seront annoncés à l'été 2025.
Bausch Health (NYSE/TSX: BHC) und ihr GI-Geschäft, Salix Pharmaceuticals, haben ihr Stipendienprogramm für gastrointestinale Gesundheit 2025 angekündigt. Die Initiative wird zehn Stipendien von bis zu 10.000 $ jeweils für Studenten, die an GI-Erkrankungen leiden und eine höhere Bildung anstreben, vergeben.
Dies ist das sechste aufeinanderfolgende Jahr des Programms, das Studenten unterstützt, die zwei- oder vierjährigen Colleges, Universitäten oder fortgeschrittene Berufs-/Technikschulen im akademischen Jahr 2025-2026 besuchen. Die Stipendien sind in drei Kategorien verfügbar: Preisträger-Stipendien für Bachelor-Studierende, Preisträger-Stipendien für Graduierten-Studierende und Stipendien für berufstätige und/oder alleinerziehende Eltern.
Bewerber müssen eine Online-Bewerbung ausfüllen, Referenzschreiben einreichen und einen Aufsatz über die Auswirkungen ihrer GI-Bedingung auf ihr Leben und die Rolle ihres Gesundheitsdienstleisters schreiben. Der Bewerbungszeitraum endet am 5. Mai 2025, und die Gewinner werden im Sommer 2025 bekannt gegeben.
- None.
- None.
Bausch Health to Provide Scholarships to 10 Students Living with GI Diseases
LAVAL, QC / ACCESS Newswire / February 10, 2025 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) and its gastroenterology (GI) business, Salix Pharmaceuticals ("Salix"), today announced the opening of the 2025 Salix Gastrointestinal Health Scholars Program application period. The program will award 10 exceptional students living with GI disease a scholarship of up to
"For the sixth consecutive year, Bausch Health is honored to offer The Salix Gastrointestinal Health Scholarship to financially support students who are driven to persevere through their GI diseases and disorders while still exceling in their academic goals. Through this scholarship program, Salix is able to uphold our commitment to support GI patients and make a difference in the lives of all communities we serve," said Aimee Lenar, Executive Vice President, US Pharma, Bausch Health.
Students can apply for this scholarship by completing the online application, submitting letters of reference, and writing an essay on the impact having a diagnosed GI condition has had on their life and the role that a health care provider played in helping to manage their condition. Scholarships are offered to school applicants or current attendees of a two- or four-year college, university, or an advanced (post-high school) vocational or technical school for the 2025 - 2026 academic year and are available in the following categories:
Undergraduate Scholar Awards for students pursuing undergraduate degrees.
Graduate Scholar Awards for students pursuing graduate degrees.
Working and/or Single Parents Scholar Award for students who are working parents and/or single parents pursuing undergraduate, vocational/technical, or graduate degrees.
The application period for the Salix Gastrointestinal Health Scholars Program will close on May 5, 2025, and scholarship recipients will be notified in the summer of 2025. To learn more about the scholarship, including eligibility criteria, terms and conditions, please visit www.salix.com/scholarship.
About Bausch Health
Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) is a global, diversified pharmaceutical company enriching lives through our relentless drive to deliver better health outcomes. We develop, manufacture and market a range of products primarily in gastroenterology, hepatology, neurology, dermatology, dentistry, aesthetics, international pharmaceuticals and eye health, through our controlling interest in Bausch + Lomb Corporation. Our ambition is to be a globally integrated healthcare company, trusted and valued by patients, HCPs, employees and investors. Our gastroenterology business, Salix Pharmaceuticals, is one of the largest specialty pharmaceutical businesses in the world and has licensed, developed and marketed innovative products for the treatment of gastrointestinal diseases for more than 30 years. For more information about Salix, visit www.Salix.com and connect with us on Twitter and LinkedIn. For more information about Bausch Health, visit www.bauschhealth.com and connect with us on LinkedIn
©2025 Salix Pharmaceuticals or its affiliates.
Investor Contact:
Garen Sarafian
ir@bauschhealth.com
877-281-6642 (toll-free)
Media Contact:
Katie Savastano
corporate.communications@bauschhealth.com
(908) 569-3692
SOURCE: Bausch Health Companies Inc.
View the original press release on ACCESS Newswire
FAQ
What is the value of each scholarship in BHC's 2025 Salix Gastrointestinal Health Scholars Program?
When is the application deadline for BHC's 2025 Salix GI Health Scholars Program?
How many scholarships will BHC award through the 2025 Salix GI Health Scholars Program?
What are the categories of scholarships available in BHC's 2025 Salix Program?
What documents are required for BHC's 2025 Salix scholarship application?
